RxDoctor Payments Data

Todd Reinhart, MD

Family Medicine · Georgetown, KYNPI 1427098250

Payments from drug & device makers

$11,148in general payments, 2019–2025

Across 712 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$890
  • AstraZeneca$846
  • Pfizer$702
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$11,128100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)135$1,830
Novo Nordisk94$1,236
GSK74$1,081
Lilly USA, LLC59$890
AstraZeneca40$846
Pfizer48$702
Amgen25$455
Boehringer Ingelheim29$418
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$331
Abbott12$235
Sumitomo Pharma America, Inc.11$201
Novartis13$184
Astellas Pharma US Inc9$170
Grifols USA, LLC7$163
Biohaven Pharmaceuticals, Inc.8$149
Takeda Pharmaceuticals U.S.A., Inc.8$140
Bayer7$129
Johnson & Johnson8$125
Antares Pharma, Inc.7$125
Sunovion Pharmaceuticals Inc.7$122
Teva Pharmaceuticals USA, Inc.3$115
Phathom Pharmaceuticals, Inc.5$113
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$106
Sanofi-aventis U.S. LLC7$102
Exact Sciences6$99
Biohaven Pharmaceutical Holding Company Ltd.5$94
Merck6$89
Axsome Therapeutics, Inc.3$72
Halozyme Inc3$69
Otsuka America Pharmaceutical, Inc.3$62
Hologic Sales And Service, LLC3$53
Lundbeck LLC2$48
Radius Health, Inc.2$40
Medtronic2$38
Alkermes, Inc.1$35
Corcept Therapeutics2$33
Genentech USA, Inc.2$32
Eisai Inc.2$32
Tolmar, Inc.2$31
Otsuka Pharmaceutical Development & Commercialization, Inc.1$29
Kowa Pharmaceuticals America, Inc.2$26
Esperion Therapeutics, Inc.2$25
Amarin Pharma, Inc.2$24
Bardy Diagnostics, Inc.1$21
Azurity Pharmaceuticals, Inc.1$20
Phadia US Inc.1$20
Baxter Healthcare1$17
Mylan Specialty L.p.1$17
Idorsia Pharmaceuticals US Inc1$16
Redhill Biopharma Inc.1$16
Verona Pharma, Inc.1$16
Philips North America LLC1$15
3b Medical, Inc.1$14
Xeris Pharmaceuticals, Inc.1$14
Sanofi Pasteur Inc.1$14
Lucid Diagnostics Inc.1$14
Ironwood Pharmaceuticals, Inc1$13
Inogen, Inc.1$12
Endogastric Solutions, Inc1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,148 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$89,941
Medicare patients
185
Services billed
1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$137,944
JardianceEmpagliflozin76$92,217
EliquisApixaban81$69,863
MounjaroTirzepatide57$66,750
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$63,352
XareltoRivaroxaban67$61,739
JanuviaSitagliptin Phosphate41$52,015
RybelsusSemaglutide14$28,347
MyrbetriqMirabegron30$28,128
TrulicityDulaglutide21$25,432
Lamictal XrLamotrigine13$25,064
FarxigaDapagliflozin Propanediol17$20,767
Breo ElliptaFluticasone/Vilanterol28$15,931
GemtesaVibegron18$15,208
Tresiba Flextouch U-100Insulin Degludec11$15,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,236$166,291119 claims
Boehringer IngelheimJardiance$418$92,21776 claims
Lilly USA, LLCMounjaro, Trulicity$890$92,18278 claims
GSKTrelegy Ellipta, Breo Ellipta$1,081$79,28398 claims
PfizerEliquis, Premarin$702$73,830101 claims
Johnson & JohnsonXarelto$125$61,73967 claims
MerckJanuvia$89$52,01541 claims
Astellas Pharma US IncMyrbetriq$170$28,12830 claims
AstraZenecaFarxiga, Symbicort$846$24,18330 claims
Sumitomo Pharma America, Inc.Gemtesa$201$15,20818 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$140$10,87311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →